---
title: "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688336.SH.md"
symbol: "688336.SH"
name: "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T07:23:32.018Z"
locales:
  - [en](https://longbridge.com/en/quote/688336.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688336.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688336.SH.md)
---

# Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH)

## Company Overview

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.3s-guojian.com](https://www.3s-guojian.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: A (0.16)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 1 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 248.95% |  |
| Net Profit YoY | 315.19% |  |
| P/B Ratio | 4.62 |  |
| Dividend Ratio | 0.19% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 39881763617.46 |  |
| Revenue | 4326916044.26 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 41.63% | A |
| Profit Margin | 68.87% | A |
| Gross Margin | 80.71% | A |
| Revenue YoY | 248.95% | A |
| Net Profit YoY | 315.19% | A |
| Total Assets YoY | 48.11% | A |
| Net Assets YoY | 52.19% | A |
| Cash Flow Margin | 93.82% | C |
| OCF YoY | 248.95% | A |
| Turnover | 0.58 | B |
| Gearing Ratio | 4.11% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "248.95%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "315.19%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.19%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "39881763617.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4326916044.26",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "41.63%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "68.87%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "80.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "248.95%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "315.19%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "48.11%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "52.19%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "93.82%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "248.95%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.58",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "4.11%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.38 | 1/81 | 47.42 | 44.29 | 41.19 |
| PB | 4.62 | 55/81 | 6.59 | 6.17 | 5.80 |
| PS (TTM) | 9.22 | 44/81 | 28.93 | 26.98 | 25.45 |
| Dividend Yield | 0.19% | 38/81 | 0.22% | 0.20% | 0.16% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 63.48 |
| Highest Target | 89.17 |
| Lowest Target | 89.17 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688336.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688336.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688336.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**